Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

FGF19 Analog as a Surgical Factor Mimetic That Contributes to Metabolic Effects Beyond Glucose Homeostasis.

DePaoli AM, Zhou M, Kaplan DD, Hunt SC, Adams TD, Learned RM, Tian H, Ling L.

Diabetes. 2019 Jun;68(6):1315-1328. doi: 10.2337/db18-1305. Epub 2019 Mar 12.

2.

NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis.

Harrison SA, Rossi SJ, Paredes AH, Trotter JF, Bashir MR, Guy CD, Banerjee R, Jaros MJ, Owers S, Baxter BA, Ling L, DePaoli AM.

Hepatology. 2019 Feb 25. doi: 10.1002/hep.30590. [Epub ahead of print]

PMID:
30805949
3.

Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis.

Zhou M, Learned RM, Rossi SJ, Tian H, DePaoli AM, Ling L.

J Lipid Res. 2019 Mar;60(3):550-565. doi: 10.1194/jlr.M089961. Epub 2019 Jan 24.

4.

Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.

Rinella ME, Trotter JF, Abdelmalek MF, Paredes AH, Connelly MA, Jaros MJ, Ling L, Rossi SJ, DePaoli AM, Harrison SA.

J Hepatol. 2019 Apr;70(4):735-744. doi: 10.1016/j.jhep.2018.11.032. Epub 2018 Dec 8.

5.

Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.

Hirschfield GM, Chazouillères O, Drenth JP, Thorburn D, Harrison SA, Landis CS, Mayo MJ, Muir AJ, Trotter JF, Leeming DJ, Karsdal MA, Jaros MJ, Ling L, Kim KH, Rossi SJ, Somaratne RM, DePaoli AM, Beuers U.

J Hepatol. 2019 Mar;70(3):483-493. doi: 10.1016/j.jhep.2018.10.035. Epub 2018 Nov 9.

6.

NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Mayo MJ, Wigg AJ, Leggett BA, Arnold H, Thompson AJ, Weltman M, Carey EJ, Muir AJ, Ling L, Rossi SJ, DePaoli AM.

Hepatol Commun. 2018 Aug 30;2(9):1037-1050. doi: 10.1002/hep4.1209. eCollection 2018 Sep.

7.

Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis.

Brandl K, Hartmann P, Jih LJ, Pizzo DP, Argemi J, Ventura-Cots M, Coulter S, Liddle C, Ling L, Rossi SJ, DePaoli AM, Loomba R, Mehal WZ, Fouts DE, Lucey MR, Bosques-Padilla F, Mathurin P, Louvet A, Garcia-Tsao G, Verna EC, Abraldes JG, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross D, Stärkel P, Ho SB, Bataller R, Schnabl B.

J Hepatol. 2018 Aug;69(2):396-405. doi: 10.1016/j.jhep.2018.03.031. Epub 2018 Apr 12.

8.

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Harrison SA, Rinella ME, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, Kugelmas M, Bashir MR, Jaros MJ, Ling L, Rossi SJ, DePaoli AM, Loomba R.

Lancet. 2018 Mar 24;391(10126):1174-1185. doi: 10.1016/S0140-6736(18)30474-4. Epub 2018 Mar 5. Erratum in: Lancet. 2018 Mar 24;391(10126):e16.

PMID:
29519502
9.

Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice.

Zhou M, Learned RM, Rossi SJ, DePaoli AM, Tian H, Ling L.

Hepatol Commun. 2017 Oct 16;1(10):1024-1042. doi: 10.1002/hep4.1108. eCollection 2017 Dec.

10.

Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice.

Hartmann P, Hochrath K, Horvath A, Chen P, Seebauer CT, Llorente C, Wang L, Alnouti Y, Fouts DE, Stärkel P, Loomba R, Coulter S, Liddle C, Yu RT, Ling L, Rossi SJ, DePaoli AM, Downes M, Evans RM, Brenner DA, Schnabl B.

Hepatology. 2018 Jun;67(6):2150-2166. doi: 10.1002/hep.29676. Epub 2018 Apr 16.

11.

Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15.

Zhou M, Luo J, Chen M, Yang H, Learned RM, DePaoli AM, Tian H, Ling L.

J Hepatol. 2017 Jun;66(6):1182-1192. doi: 10.1016/j.jhep.2017.01.027. Epub 2017 Feb 9.

12.

Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice.

Zhou M, Learned RM, Rossi SJ, DePaoli AM, Tian H, Ling L.

Hepatology. 2016 Mar;63(3):914-29. doi: 10.1002/hep.28257. Epub 2015 Nov 30.

13.

Lymphoma in acquired generalized lipodystrophy.

Brown RJ, Chan JL, Jaffe ES, Cochran E, DePaoli AM, Gautier JF, Goujard C, Vigouroux C, Gorden P.

Leuk Lymphoma. 2016;57(1):45-50. doi: 10.3109/10428194.2015.1040015. Epub 2015 May 12.

14.

A nontumorigenic variant of FGF19 treats cholestatic liver diseases.

Luo J, Ko B, Elliott M, Zhou M, Lindhout DA, Phung V, To C, Learned RM, Tian H, DePaoli AM, Ling L.

Sci Transl Med. 2014 Jul 30;6(247):247ra100. doi: 10.1126/scitranslmed.3009098.

15.

20 years of leptin: leptin in common obesity and associated disorders of metabolism.

DePaoli AM.

J Endocrinol. 2014 Oct;223(1):T71-81. doi: 10.1530/JOE-14-0258. Epub 2014 Jun 27. Review.

PMID:
24973357
16.

Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.

Zhou M, Wang X, Phung V, Lindhout DA, Mondal K, Hsu JY, Yang H, Humphrey M, Ding X, Arora T, Learned RM, DePaoli AM, Tian H, Ling L.

Cancer Res. 2014 Jun 15;74(12):3306-16. doi: 10.1158/0008-5472.CAN-14-0208. Epub 2014 Apr 11.

17.

Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?

DePaoli AM, Higgins LS, Henry RR, Mantzoros C, Dunn FL; INT131-007 Study Group.

Diabetes Care. 2014 Jul;37(7):1918-23. doi: 10.2337/dc13-2480. Epub 2014 Apr 10.

PMID:
24722496
18.

Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet.

Shetty GK, Matarese G, Magkos F, Moon HS, Liu X, Brennan AM, Mylvaganam G, Sykoutri D, Depaoli AM, Mantzoros CS.

Eur J Endocrinol. 2011 Aug;165(2):249-54. doi: 10.1530/EJE-11-0252. Epub 2011 May 20.

19.

Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes.

Mittendorfer B, Horowitz JF, DePaoli AM, McCamish MA, Patterson BW, Klein S.

Diabetes. 2011 May;60(5):1474-7. doi: 10.2337/db10-1302. Epub 2011 Mar 16.

20.

Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes.

Dunn FL, Higgins LS, Fredrickson J, DePaoli AM; INT131-004 study group.

J Diabetes Complications. 2011 May-Jun;25(3):151-8. doi: 10.1016/j.jdiacomp.2010.06.006. Epub 2010 Aug 23.

PMID:
20739195
21.

Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation.

Higgins LS, Depaoli AM.

Am J Clin Nutr. 2010 Jan;91(1):267S-272S. doi: 10.3945/ajcn.2009.28449E. Epub 2009 Nov 11. Review.

PMID:
19906796
22.

The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia.

Mulligan K, Khatami H, Schwarz JM, Sakkas GK, DePaoli AM, Tai VW, Wen MJ, Lee GA, Grunfeld C, Schambelan M.

J Clin Endocrinol Metab. 2009 Apr;94(4):1137-44. doi: 10.1210/jc.2008-1588. Epub 2009 Jan 27.

23.

Blood pressure and vascular effects of leptin in humans.

Brook RD, Bard RL, Bodary PF, Eitzman DT, Rajagopalan S, Sun Y, Depaoli AM.

Metab Syndr Relat Disord. 2007 Sep;5(3):270-4. doi: 10.1089/met.2006.0023.

24.

Effects of leptin replacement on macro- and micronutrient preferences.

Licinio J, Ribeiro L, Busnello JV, Delibasi T, Thakur S, Elashoff RM, Sharma A, Jardack PM, Depaoli AM, Wong ML.

Int J Obes (Lond). 2007 Dec;31(12):1859-63. Epub 2007 Aug 7.

PMID:
17684509
25.

Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy.

Park JY, Javor ED, Cochran EK, DePaoli AM, Gorden P.

Metabolism. 2007 Apr;56(4):508-16.

26.

Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.

Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyanaga F, Kobayashi N, Tanaka T, Chusho H, Miyazawa T, Hayashi T, Hosoda K, Ogawa Y, DePaoli AM, Fukushima M, Nakao K.

J Clin Endocrinol Metab. 2007 Feb;92(2):532-41. Epub 2006 Nov 21.

PMID:
17118991
27.

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004.

Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM.

J Bone Miner Res. 2005 Dec;20(12):2275-82. No abstract available.

28.

Leptin replacement therapy modulates circulating lymphocyte subsets and cytokine responsiveness in severe lipodystrophy.

Oral EA, Javor ED, Ding L, Uzel G, Cochran EK, Young JR, DePaoli AM, Holland SM, Gorden P.

J Clin Endocrinol Metab. 2006 Feb;91(2):621-8. Epub 2005 Nov 29.

PMID:
16317060
29.

Recombinant osteoprotegerin for juvenile Paget's disease.

Cundy T, Davidson J, Rutland MD, Stewart C, DePaoli AM.

N Engl J Med. 2005 Sep 1;353(9):918-23.

30.

Long-term efficacy of leptin replacement in patients with generalized lipodystrophy.

Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P.

Diabetes. 2005 Jul;54(7):1994-2002.

31.

Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.

Javor ED, Ghany MG, Cochran EK, Oral EA, DePaoli AM, Premkumar A, Kleiner DE, Gorden P.

Hepatology. 2005 Apr;41(4):753-60.

PMID:
15791619
32.

Effect of leptin replacement on brain structure in genetically leptin-deficient adults.

Matochik JA, London ED, Yildiz BO, Ozata M, Caglayan S, DePaoli AM, Wong ML, Licinio J.

J Clin Endocrinol Metab. 2005 May;90(5):2851-4. Epub 2005 Feb 15.

PMID:
15713712
34.
35.

Endocrine and metabolic effects of physiologic r-metHuLeptin administration during acute caloric deprivation in normal-weight women.

Schurgin S, Canavan B, Koutkia P, Depaoli AM, Grinspoon S.

J Clin Endocrinol Metab. 2004 Nov;89(11):5402-9.

PMID:
15531489
36.

Congenital leptin deficiency due to homozygosity for the Delta133G mutation: report of another case and evaluation of response to four years of leptin therapy.

Gibson WT, Farooqi IS, Moreau M, DePaoli AM, Lawrence E, O'Rahilly S, Trussell RA.

J Clin Endocrinol Metab. 2004 Oct;89(10):4821-6.

PMID:
15472169
37.

Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency.

McDuffie JR, Riggs PA, Calis KA, Freedman RJ, Oral EA, DePaoli AM, Yanovski JA.

J Clin Endocrinol Metab. 2004 Sep;89(9):4258-63.

38.

Recombinant human leptin in women with hypothalamic amenorrhea.

Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A, Mantzoros CS.

N Engl J Med. 2004 Sep 2;351(10):987-97.

39.

Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy.

Javor ED, Moran SA, Young JR, Cochran EK, DePaoli AM, Oral EA, Turman MA, Blackett PR, Savage DB, O'Rahilly S, Balow JE, Gorden P.

J Clin Endocrinol Metab. 2004 Jul;89(7):3199-207.

PMID:
15240593
40.

Leptin hormonal kinetics in the fed state: effects of adiposity, age, and gender on endogenous leptin production and clearance rates.

Wong SL, DePaoli AM, Lee JH, Mantzoros CS.

J Clin Endocrinol Metab. 2004 Jun;89(6):2672-7.

PMID:
15181040
41.

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women.

Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM.

J Bone Miner Res. 2004 Jul;19(7):1059-66. Epub 2004 Mar 1.

42.

Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults.

Licinio J, Caglayan S, Ozata M, Yildiz BO, de Miranda PB, O'Kirwan F, Whitby R, Liang L, Cohen P, Bhasin S, Krauss RM, Veldhuis JD, Wagner AJ, DePaoli AM, McCann SM, Wong ML.

Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4531-6. Epub 2004 Mar 9.

43.

Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy.

Moran SA, Patten N, Young JR, Cochran E, Sebring N, Reynolds J, Premkumar A, Depaoli AM, Skarulis MC, Oral EA, Gorden P.

Metabolism. 2004 Apr;53(4):513-9.

PMID:
15045701
44.

The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men.

Chan JL, Heist K, DePaoli AM, Veldhuis JD, Mantzoros CS.

J Clin Invest. 2003 May;111(9):1409-21.

45.

Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy.

Simha V, Szczepaniak LS, Wagner AJ, DePaoli AM, Garg A.

Diabetes Care. 2003 Jan;26(1):30-5.

PMID:
12502655
46.

Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency.

Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, Sanna V, Jebb SA, Perna F, Fontana S, Lechler RI, DePaoli AM, O'Rahilly S.

J Clin Invest. 2002 Oct;110(8):1093-103.

47.

Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy.

Oral EA, Ruiz E, Andewelt A, Sebring N, Wagner AJ, Depaoli AM, Gorden P.

J Clin Endocrinol Metab. 2002 Jul;87(7):3110-7.

PMID:
12107209
48.

Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.

Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI.

J Clin Invest. 2002 May;109(10):1345-50.

49.

Leptin-replacement therapy for lipodystrophy.

Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A.

N Engl J Med. 2002 Feb 21;346(8):570-8.

50.

Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat.

Tokuyama Y, Sturis J, DePaoli AM, Takeda J, Stoffel M, Tang J, Sun X, Polonsky KS, Bell GI.

Diabetes. 1995 Dec;44(12):1447-57.

PMID:
7589853

Supplemental Content

Loading ...
Support Center